Biguanide Dimer Copper Chelation for Macrophage Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, including COVID-19, lack effective strategies to manage cytokine release syndrome (CRS) caused by uncontrolled cytokine production in inflammatory macrophages, and existing drugs like metformin have moderate potency and limited understanding of underlying mechanisms.
Innovation Solution
Development of highly potent compounds with two biguanidyl radicals that chelate mitochondrial copper, inhibiting the production of α-ketoglutarate and blocking macrophage activation, thereby regulating cytokine expression and cell plasticity, and forming a complex with copper to exert anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin and existing biguanide derivatives are used to treat inflammatory diseases and cancer, then some therapeutic effect is achieved, but the potency is moderate and the mechanism of action is not fully understood
Solution Approach 1:
The patent modifies the chemical structure of biguanide derivatives by introducing specific substituents and functional groups to enhance copper chelation capability. This structural parameter change results in compounds with 1,000-fold greater efficacy than metformin while providing clearer mechanistic insight through defined copper binding sites and pathways.
Solution Approach 2:
The patent identifies copper as a key intermediary element in the mechanism of action. The new biguanide compounds directly chelate mitochondrial copper, which serves as a mediator between the drug and its target processes (α-ketoglutarate production, cytokine expression, cell plasticity). This intermediary approach clarifies the mechanism while enhancing efficacy.
2Reliability
If existing drugs like metformin are used to block macrophage activation, then some inhibition is achieved, but the potency is limited compared to the need for effective CRS management
Solution Approach 1:
The patent optimizes the chemical parameters of the biguanide compounds, particularly the basicity and chelation capacity, to achieve 1,000-fold greater potency than metformin. This parameter optimization enables effective blocking of macrophage activation at much lower concentrations, addressing the productivity requirement for potent CRS management.
3Object-affected harmful factors
If copper chelation is used to inhibit α-ketoglutarate production and block macrophage activation, then anti-inflammatory effect is achieved, but the complexity of the mechanism increases
Solution Approach 1:
The patent extracts copper as the critical element mediating harmful cytokine production. By focusing the mechanism on copper chelation and its direct impact on α-ketoglutarate production and histone modifications, the complex pathway is simplified to a manageable intervention point, reducing perceived mechanism complexity while maintaining effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate 1,000-fold greater efficacy than metformin in preventing macrophage activation and show potential as anti-inflammatory agents, offering a new approach for treating inflammatory diseases and cancer, including COVID-19, by effectively regulating cytokine production and cell plasticity.
Implementation Method 1
Copper is used in mitochondria to replenish the pool of NAD+, the enzymatic co-substrate required for the production of α-ketoglutarate (αKG) and acetyl-coenzyme A (acetyl-CoA)
Implementation Method 2
they have developed highly potent compounds comprising biguanidyl radicals that blocks the oxidation of NADH into NAD+ by chelating mitochondrial copper
Implementation Method 3
CD44 mediates endocytosis of the d-block metals copper and iron through interactions with hyaluronates in inflammatory macrophages
Implementation Method 4
epigenetic reprogramming regulates monocyte-to-macrophage transition during inflammation
Data Source
AI summary
The present invention relates to compounds comprising two biguanidyl radicals that can be useful as anti-inflammatory agent, and also to new compounds comprising two biguanidyl radicals and their use as a drug, in particular for treating a cancer, a metabolic disease, a secondary mitochondrial disorder due to copper overload including Indian childhood cirrhosis, Wilson's disease and Idiopathic infantile copper toxicosis or due to iron overload, an infection by a virus such as a coronavirus or an influenza virus, a neurodegenerative disease or disorder and aging.